InvestorsPrism
  • Home
  • Indexes
    • All Indexes
    • Cannabis
    • EV
    • Gene Therapy
    • MedDevices
    • MedDiagnostics
    • Solar
    • Uranium
    • Vaccines & Cell Therapy
    • Web 3.0
  • Companies
  • Trending News
    • Latest
    • Markets
    • Finance
    • Economy
    • Technology
    • Earnings
    • Healthcare
    • Prism Daily
  • Equity Research
    • Login
    • Register
    • User Profile
    • Log Out
  • Home
  • Indexes
    • All Indexes
    • Cannabis
    • EV
    • Gene Therapy
    • MedDevices
    • MedDiagnostics
    • Solar
    • Uranium
    • Vaccines & Cell Therapy
    • Web 3.0
  • Companies
  • Trending News
    • Latest
    • Markets
    • Finance
    • Economy
    • Technology
    • Earnings
    • Healthcare
    • Prism Daily
  • Equity Research
    • Login
    • Register
    • User Profile
    • Log Out

Home News Feeds MedDiagnostics

Feed Category: MedDiagnostics

February 07 at 5:00 pm

Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023

FRIENDSWOOD, Texas, February 07, 2023–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it… [Read More]
February 07 at 10:07 am

15 Worst Stock Picks of Cathie Wood in 2022

In this piece, we will take a look at the 15 worst stock picks of Cathie Wood in 2022. For her top five worst stock… [Read More]
February 07 at 10:00 am

Genetic Technologies Announces Closing of $5 Million Registered Direct Offering

Genetic Technologies LtdMELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven… [Read More]
February 07 at 8:00 am

Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023

ENGLEWOOD, CO / ACCESSWIRE / February 7, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company… [Read More]
February 07 at 8:00 am

BioSig Appoints Former Qorvo CFO as Successor to Steve Chaussy

BioSig Technologies, Inc.Westport, CT, Feb. 07, 2023 (GLOBE NEWSWIRE) –Chief Financial Officer Steve Chaussy retires following 12 years of serviceSteve Buhaly joins BioSig as CFOBuhaly… [Read More]
February 07 at 7:15 am

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

Myriad Genetics, Inc.SALT LAKE CITY, Feb. 07, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted… [Read More]
February 07 at 7:05 am

2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET

OraSure Technologies, Inc.BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth… [Read More]
February 07 at 6:37 am

Quite a few insiders invested in OraSure Technologies, Inc. (NASDAQ:OSUR) last year which is positive news for shareholders

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case… [Read More]
February 06 at 5:00 pm

Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023

SOUTH SAN FRANCISCO, Calif., February 06, 2023–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year… [Read More]
February 06 at 4:05 pm

T2 Biosystems Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation’s LymeX Diagnostics Prize

T2 Biosystems, Inc.LEXINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic… [Read More]
February 06 at 4:01 pm

Personalis to Participate at Upcoming Investor Conferences

FREMONT, Calif., February 06, 2023–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at… [Read More]
February 06 at 1:41 pm

Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down

Needham has upgraded Personalis Inc (NASDAQ: PSNL) to Buy from Hold with a price target of $8.The analyst writes that Personalis’s cash burn has likely peaked and expects it… [Read More]

Posts navigation

Page 1 Page 2 … Page 9 Next page
InvestorsPrism

Copyright © 2023 Investors Prism
All rights reserved

Company

  • About Us
  • Contact Us
  • Privacy Policy
  • Disclaimer

News

  • Latest
  • Markets
  • Finance
  • Economy
  • Technology
  • Earnings
  • Healthcare
  • Prism Daily

Indexes

  • Cannabis
  • EV
  • Gene Therapy
  • MedDevices
  • MedDiagnostics
  • Solar
  • Uranium
  • Vaccines & Cell Therapy
  • Web 3.0